GeNeuro and Verily Collaborate to Progress Long-COVID Research
Friday, October 20, 2023
GeNeuro, a biopharmaceutical company listed on Euronext Paris under the symbol GNRO, has announced a strategic collaboration with Verily, a precision health technology company within Alphabet. The aim of this partnership is to investigate biomarkers associated with the activation of the proinflammatory HERV-W envelope protein (W-ENV) in individuals infected with SARS-CoV-2.
This collaboration builds upon GeNeuro's earlier findings, which were published in Cell Press this year. These findings demonstrated that SARS-CoV-2 can trigger the in vitro activation of the HERV-W in susceptible individuals, and that there is a correlation between the levels of the W-ENV protein in serum and lymphocytes and the severity of COVID-19.
GeNeuro, expressed, "Our research suggests that W-ENV plays a role in the severity of COVID-19 and may offer insights into the symptoms of long-COVID. This collaboration with Verily aligns with GeNeuro's mission to develop personalized treatments for long-COVID by identifying biomarkers that can help predict severe disease outcomes."
Verily will contribute to the collaboration by providing high-resolution multi-omic data collected from samples of COVID-19 patients. This data will be obtained using Immune Profiler, Verily's cutting-edge immune mapping platform, and will be subjected to high-powered data analysis within Workbench, a secure research environment designed for the comprehensive analysis of multimodal biomedical data. Both Immune Profiler and Workbench are part of Verily's broader suite of products, which are intended to advance the field of precision health by utilizing diverse datasets to accelerate medical research.
Charlie Kim, Head of Molecular Science at Verily, expressed enthusiasm about the collaboration, stating, "We are thrilled to partner with GeNeuro in pursuit of our shared belief that early identification of actionable biomarkers in disease can enhance precision health and ultimately save lives. This partnership could represent a significant step towards more timely and targeted interventions for individuals suffering from long-COVID."
Source: businesswire.com
